This Article Abstract Full Text (PDF) All Versions of this Article: 40/5/694    most recent 01.HYP.0000035395.51441.10v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsumura, K. Articles by Iida, M. Search for Related Content PubMed PubMed Citation Articles by Matsumura, K. Articles by Iida, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Autonomic, reflex, and neurohumoral control of circulation

(Hypertension. 2002;40:694.)
© 2002 American Heart Association, Inc.

Scientific Contributions

Central Ghrelin Modulates Sympathetic Activity in Conscious Rabbits

Kiyoshi Matsumura; Takuya Tsuchihashi; Koji Fujii; Isao Abe; Mitsuo Iida

From the Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Correspondence to Kiyoshi Matsumura, MD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812-8582, Japan. E-mail matsumk{at}intmed2.med.kyushu-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Ghrelin is an orexigenic peptide originally isolated from the stomach. Intravenous administration of ghrelin has been shown to elicit a decrease in arterial pressure without a significant change in heart rate (HR), suggesting that ghrelin may act on the central nervous system to modulate sympathetic activity. The aim of the present study was to determine the central effects of ghrelin on cardiovascular and sympathetic responses in conscious rabbits. Intravenous injection of ghrelin elicited dose-related decreases in arterial pressure and HR, without a significant change in renal sympathetic nerve activity. On the other hand, intracerebroventricular injection of 1 nmol of ghrelin decreased arterial pressure, HR, and renal sympathetic nerve activity. Peak depressor or sympathoinhibitory responses of mean arterial pressure and renal sympathetic nerve activity (-19.0±1.5 mm Hg and -43.3±5.4%) were observed at 50 and 40 minutes, respectively, after intracerebroventricular injection of 1 nmol of ghrelin. Furthermore, a subdepressor dose of intracerebroventricular infusion of ghrelin (0.3 nmol/150 µL per hour) significantly augmented the baroreflex sensitivities assessed by renal sympathetic nerve activity and HR compared with those of vehicle infusion (G_max; -17.8±3.1 versus -9.4±1.6%/mm Hg, P<0.05; -12.5±1.8 versus -6.6±1.2 bpm/mm Hg, P<0.05; respectively). These results suggest that intravenous injection of ghrelin acts, at least in part, on the central nervous system to decrease arterial pressure and renal sympathetic nerve activity, and that central ghrelin participates in the regulations of the sympathetic nerve activity to the kidney and the baroreceptor reflex in conscious rabbits.

Key Words: baroreceptors • blood pressure • central nervous system • ghrelin • nervous system, sympathetic renal

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Ghrelin, an acylated 28-residue peptide originally isolated from the rat stomach, is an endogenous ligand for the growth hormone (GH) secretagogue receptor.^1,2 Although ghrelin is likely to regulate pituitary GH secretion along with GH-releasing hormone and somatostatin,^2,3 GH secretagogue receptors have also been identified in hypothalamic neurons and in the brainstem.^4,5 Intracerebroventricular (ICV) administration of ghrelin has been shown to generate a dose-dependent increase in food intake and body weight,^6,7 suggesting that ghrelin participates in the regulation of food intake and GH secretion. Furthermore, ICV administration of ghrelin has been shown to increase plasma vasopressin level without a significant change in arterial pressure in conscious rats.⁸

It has also been reported that intravenous injection of human ghrelin elicits a decrease in blood pressure without an increase in heart rate (HR) in healthy men.⁹ In addition, plasma ghrelin concentration is increased in patients with cachexia associated with chronic heart failure.¹⁰ These previous findings suggest that ghrelin may participate not only in feeding behavior but also in cardiovascular and sympathetic regulation. Although ghrelin has been reported to have a vasodilatory effect in humans,¹¹ the underlying mechanisms of depressor response induced by intravenous injection of ghrelin have not yet been determined. Because the depressor response was not accompanied by tachycardia, it is likely that mechanisms other than direct vasodilating effects, at least in part, are involved in this depressor response. To clarify the mechanisms for this depressor response, the effects of ghrelin on sympathetic activity and on the baroreceptor reflex should be determined. We hypothesized that intravenous administration of ghrelin acts at the central nervous system to modulate the sympathetic nervous system, resulting in a decrease in arterial pressure without tachycardia. Accordingly, in the present study, we focused on the central effect of ghrelin on sympathetic activity and baroreceptor reflex. To evaluate the sympathetic nervous system precisely, the present study was conducted on conscious rabbits with direct recording of renal sympathetic nerve activity (RSNA), because the sympathetic nervous system and baroreceptor reflex are greatly affected by anesthesia.^12,13

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Preparation of Animals
The experiments were conducted with 24 male Japanese White rabbits (Biotek, Saga, Japan) weighing 2.5 to 2.7 kg. All experiments were performed according to the institutional guidelines for animal experimentation at Kyushu University. Rabbits were anesthetized with pentobarbital sodium (30 mg/kg IV). Three days before experimentation, bipolar electrodes were implanted on the left renal sympathetic nerve, and a stainless steel cannula was placed in the right lateral cerebral ventricle.^14,15 RSNA was recorded as described previously.^14,15 At least 3 days after the surgical procedures, the following experiments were performed on conscious rabbits placed in a box. On the day of the experiment, polyethylene catheters (PE-50) were inserted into the central ear artery and the marginal ear vein under 1% lidocaine local anesthesia. Each experiment was started in the morning, and a >30-minute control period was obtained to get baseline levels of mean arterial pressure (MAP), HR, and RSNA. All drugs for ICV injection were dissolved in artificial cerebrospinal fluid (aCSF).^15–17

Effects of Intravenous Ghrelin on Cardiovascular and Sympathetic Responses
To determine the systemic effect of ghrelin on cardiovascular and sympathetic responses, vehicle (0.9% saline; 0.2 mL) and human ghrelin (Peptide Institute, Osaka, Japan), 1 or 5 nmol, were injected intravenously in ascending concentration order (n=6 for each). These doses of ghrelin were dissolved in 0.9% saline (0.2 mL). The administration of each dose of ghrelin was separated by a period of 60 minutes. MAP, HR, and RSNA were confirmed to return to their baseline values before each injection.

Effects of ICV Ghrelin on Cardiovascular and Sympathetic Responses
To determine the central effect of ghrelin on cardiovascular and sympathetic responses, aCSF (80 µL) or 1 nmol of human ghrelin was ICV injected (n=6 for each). This dose of ghrelin was dissolved in 80 µL aCSF.

Effects of ICV Infusion of Ghrelin on Baroreceptor Reflex
Three days after the surgical procedure, the effects of ghrelin on the baroreflex control of RSNA and HR were determined (n=6). Either aCSF or ghrelin was infused with a compact syringe pump at a flow rate of 150 µL/hour. Fifteen minutes after the beginning of the ICV infusion of either aCSF or ghrelin (0.3 nmol/hour), the sensitivities of the baroreflex control of RSNA and HR were determined as described previously.¹⁵

A progressive infusion of sodium nitroprusside (5 to 80 µg/kg per minute diluted in 0.9% NaCl) was performed to induce a 25 to 30 mm Hg decrease in MAP. Phenylephrine (2 to 32 µg/kg per minute diluted in 0.9% NaCl) was infused for 3 minutes to induce a 30 mm Hg increase in MAP. Half of the rabbits were infused first with sodium nitroprusside and then phenylephrine; the remaining rabbits received an infusion of phenylephrine before sodium nitroprusside. At least 30 minutes elapsed between the infusion of each vasoactive agent to allow MAP, HR, and RSNA to return to the baseline values.

The values of the mean RSNA before each infusion were defined as 100%. Data for the MAP-RSNA or MAP-HR relations during increases and decreases in MAP were fitted to a sigmoid logistic function curve. The equation used for the data analysis was based on the following mathematical model:^15,18

In this equation, P₁ is the range between the upper and lower plateau; P₂, a range-independent measure of slope or normalized gain; P₃, the blood pressure at the midpoint of the logistic function curve; and P₄, the lower plateau. Data were fit to the logistic function curve using a nonlinear regression program in the Statistical Analysis System (NLIN procedure, SAS Institute). In the present study, the maximum slope (G_max=-P_1xP₂/4) calculated from the parameters of the logistic function curve was considered to be the sensitivity of the baroreceptor reflex.

Statistics
All values are expressed as mean±SE. To determine the intravenous and central effects of ghrelin on cardiovascular and sympathetic responses, 1-way ANOVA with repeated measurements was performed, followed by Duncan’s multiple range test. In addition, to compare the responses induced by ICV aCSF and ghrelin, 2-way ANOVA with repeated measurements was applied. A paired t test was used to determine the effects of ICV ghrelin on baroreflex control. A value of P<0.05 was considered significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Effects of Intravenous Ghrelin on Cardiovascular and Sympathetic Responses
Baseline values for MAP and HR before the intravenous injection of ghrelin were 87.0±1.9 mm Hg and 232.5±11.7 bpm, respectively. Intravenous injection of ghrelin elicited dose-related decreases in MAP without a significant change in RSNA. Intravenous injection of 5 nmol ghrelin decreased HR (Figure 1). Peak depressor and bradycardiac responses induced by intravenous injection of 5 nmol ghrelin were obtained at 20 and 40 minutes after injection, respectively, and MAP and HR returned to the baseline levels at 60 minutes.

View larger version (17K): [in this window] [in a new window]   Figure 1. Bar graphs showing the effects of intravenous injections of 2 doses (1 and 5 nmol) of ghrelin and vehicle (0.9% saline; 0.2 mL) on changes in MAP, HR, and integrated RSNA in 6 rabbits. Values are mean±SE. **P<0.01 vs respective responses to vehicle by Duncan’s multiple range test.

Effects of ICV Ghrelin on Cardiovascular and Sympathetic Responses
Figure 2 shows the typical responses of MAP, HR, and RSNA elicited by ICV injection of ghrelin (1 nmol). ICV injection of 1 nmol of ghrelin provoked decreases in MAP, HR, and RSNA, and peak responses (-19.0±1.5 mm Hg, -80.0±11.6 bpm, and -43.3±5.4%) were obtained at 40 to 50 minutes (Figure 3). After peak responses were observed, MAP, HR, and RSNA gradually returned to baseline levels, although these variables were still significantly decreased at 90 minutes after administration. These depressor, bradycardiac, and sympathoinhibitory responses to ICV ghrelin were also significantly different from those to ICV aCSF by 2-way ANOVA with repeated measurements (P<0.01 for each variables).

View larger version (77K): [in this window] [in a new window]   Figure 2. Representative tracings show changes in arterial pressure, MAP, HR, and RSNA induced by ICV injection of ghrelin (1 nmol) in a conscious rabbit.

View larger version (25K): [in this window] [in a new window]   Figure 3. Line graphs showing the time course of MAP, HR, and RSNA elicited by ICV injection of 1 nmol of ghrelin (•) or aCSF ( (n=6 for each). Values are mean±SE. *P<0.05, **P<0.01 vs control period by Duncan’s multiple range test. Responses of MAP, HR, and RSNA to ICV injection of ghrelin were significantly different from those to aCSF by 2-way ANOVA with repeated measurements (P<0.01 for each variables).

Effects of ICV Infusion of Ghrelin on Baroreceptor Reflex
ICV infusion of ghrelin (0.3 nmol/hour) did not cause any significant changes in MAP, HR, or RSNA, but it significantly augmented the baroreflex control of RSNA (G_max, -17.8±3.1 versus -9.4±1.6%/mm Hg; P<0.05) and HR (G_max, -12.5±1.8 versus -6.6±1.2 bpm/mm Hg; P<0.05) (Table and Figure 4). P₂ value in the logistic function curve of RSNA significantly increased during ICV infusion of ghrelin. In addition, P₁ and P₂ values in the logistic function curve of HR also significantly increased during ICV infusion of ghrelin (Table).

View this table: [in this window] [in a new window]   Parameters and Maximum Gain of Baroreflex Control of RSNA and HR During ICV Infusion of Ghrelin or aCSF

View larger version (24K): [in this window] [in a new window]   Figure 4. A, Average logistic function curves expressing the relation between MAP and RSNA during ICV infusion of aCSF (solid line) or ghrelin (dashed line) (n=6). B, Slopes of baroreflex control of RSNA with variation of MAP during ICV infusion of aCSF (solid line) or ghrelin (dashed line) (n=6). C, Average logistic function curves expressing the relation between MAP and HR during ICV infusion of aCSF (solid line) or ghrelin (dashed line) (n=6). D, Slopes of baroreflex control of HR with variation of MAP during ICV infusion of aCSF (solid line) or ghrelin (dashed line) (n=6).

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The present study demonstrated that intravenous injection of ghrelin elicited dose-related decreases in MAP without a significant change in RSNA. It has been shown that ghrelin has a vasodilating effect;¹¹ however, it seems difficult to attribute this depressor response solely to the direct vasodilating effect of ghrelin, because in the present study the depressor response was not accompanied by activations of RSNA and HR mediated by baroreceptor reflex. In contrast, ICV injection of 1 nmol ghrelin caused significant decreases in arterial pressure, HR, and RSNA. These findings suggest that systemically administered ghrelin acted, at least in part, at the central nervous system to suppress sympathetic activity, resulting in decreases in arterial pressure and HR. Slightly dissociated responses of RSNA elicited by intravenous or ICV injected ghrelin might be attributed to the different depressor mechanisms. The direct vasodilating effect and the suppression of sympathetic nervous system in the brain might participate in depressor response of intravenous injection of ghrelin. Moreover, ICV infusion of ghrelin augmented the baroreflex controls of RSNA and HR in conscious rabbits. To the best of our knowledge, this is the first study to demonstrate the central cardiovascular and sympathetic modulation by ghrelin in conscious animals.

ICV administration of ghrelin not only suppressed sympathetic outflow to the kidney but also augmented the baroreflex control of RSNA and HR in conscious rabbits. In the present study, to eliminate the direct effects of ghrelin on the heart or blood vessels and to evaluate the contribution of exogenous brain ghrelin to the baroreceptor reflex, a subdepressor dose of ghrelin was ICV infused. Accordingly, P₃ values in baroreflex curves for MAP-RSNA and MAP-HR relationships did not change during ICV infusion of ghrelin. These findings support the idea that central ghrelin participates in central cardiovascular and sympathetic modulation in 2 different manners: by suppressing the sympathetic nervous system and by augmenting the baroreceptor reflex. On the other hand, intravenous administration of ghrelin has been reported to increase the cardiac index in healthy men.⁹ These hemodynamic and sympathetic modulations by ghrelin may be beneficial in the treatment of the patients with congestive heart failure, because activation of the sympathetic nervous system and decreased cardiac function need to be treated in these patients. In fact, intravenous infusion of human ghrelin significantly increased cardiac index and stroke volume in patients with congestive heart failure.¹⁹

In the present study, ICV infusion of ghrelin significantly increased P₁ value of HR, although it failed to change P₁ value of RSNA. The different response of P₁ values of baroreflex curve might be explained by the different regulatory mechanisms between RSNA and HR. RSNA is regulated by sympathetic nervous system, whereas HR is dually regulated by the sympathetic and parasympathetic nervous system. The effect of ghrelin on the parasympathetic nervous system might be attributable to the different response of P₁ values of RSNA and HR.

ICV and intravenous injections of ghrelin caused decreases in HR. It seems difficult to evaluate separately the roles of sympathetic and parasympathetic nervous system in the present study. However, bradycardiac effects during ICV administration of ghrelin might be primarily attributable to the suppression of sympathetic nervous system, because time courses of MAP, HR, and RSNA were similar. In contrast, bradycardiac effect during intravenous administration of ghrelin might be dually modulated by sympathetic and parasympathetic nervous system, because a little dissociated response between HR and RSNA was observed. Ghrelin may have some different effects between sympathetic and parasympathetic nervous system.

Ghrelin acts at the GH secretagogue receptor, the G protein–coupled receptor, to release GH to the systemic circulation.^2,3 In fact, intravenous or ICV administration of ghrelin has been shown to increase plasma GH concentration.^9,20,21 Therefore, although plasma GH concentrations were not determined in the present study, plasma GH concentration could increase after the ICV administration of ghrelin. On the other hand, GH activity has been proposed to be associated with myocardial growth and cardiac function.^22,23 It may be important to discriminate the relative role of released GH and ghrelin itself on the cardiovascular and sympathetic effects of ICV ghrelin. In regard to feeding behavior, GH release is not considered to be involved in the ghrelin-induced orexigenic effect, because ICV injection of ghrelin can increase food intake in GH-deficient spontaneous dwarf rats.²⁴ Furthermore, Bisi et al²⁵ reported that intravenous injection of GH failed to change arterial pressure, HR, and left ventricular ejection fraction in healthy men. Based on these previous findings, the cardiovascular and sympathetic responses induced by ghrelin in the present study could be attributable to the effect of ghrelin by itself.

The present study was limited by which brain regions are involved in the regulation of blood pressure and baroreceptor reflex by ghrelin. Ghrelin is predominantly produced by the stomach, whereas substantially lower amounts are derived from bowel, pituitary, kidney, placenta, and hypothalamus.³ In contrast, GH secretagogue receptors have also been identified on hypothalamic neurons and in the brainstem.^4,5 ICV administration of ghrelin has been shown to induce c-fos expression in the neurons of the nucleus of the solitary tract and dorsomotor nucleus of the vagus,²⁶ suggesting that centrally administered ghrelin activated the neurons of these regions. The nucleus of the solitary tract, where baroreceptor and chemoreceptor afferents terminate, is one of the most important brain regions to regulate blood pressure and the sympathetic nervous system. In addition, activation of neurons in the nucleus of the solitary tract by L-glutamate, an excitatory neurotransmitter in the brain, decreases arterial pressure and inhibits RSNA.²⁷ These anatomical and physiological findings support the idea that central ghrelin might act at the medulla oblongata, such as at the nucleus of the solitary tract and dorsomotor nucleus of the vagus, and at the arcuate hypothalamic nucleus, to modulate the sympathetic nervous system and the baroreceptor reflex. A study that focuses on the microinjection of ghrelin into the hypothalamus and medulla oblongata will be necessary to clarify the role of ghrelin in the brain with regard to cardiovascular and sympathetic regulations.

Appetite and feeding behavior are regulated by many factors such as leptin and neuropeptide Y.^28,29 ICV administration of ghrelin has been shown to generate a dose-dependent increase in food intake and body weight, ^6,7 suggesting that ghrelin participates in the regulation of food intake and in the regulation of GH secretion. Leptin and ghrelin are released from white adipose tissue and the stomach, respectively, both of which enter into the systemic circulation and reach to the brain.³ During food deprivation, plasma leptin levels rapidly decline,³⁰ neuropeptide Y/agouti-related protein production is elevated, and circulating ghrelin levels increase, suggesting that leptin and ghrelin coregulate the hypothalamic peptidergic system of feeding behavior in opposite ways.^30,31 ICV ghrelin has been shown to antagonize the leptin-induced inhibition of food intake through the activation of the hypothalamic neuropeptide Y/Y₁ receptor pathway.²⁴ On the other hand, these neuropeptides involved in feeding behavior have been suggested to participate in central cardiovascular and sympathetic regulations.^{16,17,32–34} ICV administration of leptin activates sympathetic nervous system, resulting in an increase in arterial pressure.^33,34 In contrast, in the present study, ICV administration of ghrelin suppressed the sympathetic nervous system, resulting in a decrease in arterial pressure. Based on these findings, leptin and ghrelin may interact with each other and play roles in central cardiovascular and sympathetic regulations and in food intake and energy expenditure.

Chronic central administration of ghrelin has been shown to increase both neuropeptide Y and agouti-related protein (AGRP) mRNA levels in the arcuate nucleus.³⁵ ICV administration of neuropeptide Y decreases arterial pressure and RSNA in conscious rabbits.³⁶ On the other hand, AGRP is an endogenous melanocortin-3 and -4 receptor (MC3-R and MC4-R) antagonist, and central cardiovascular and sympathetic responses to ICV leptin are reportedly to be mediated through activation of hypothalamic MC3-R and MC4-R.^37–39 Based on these previous findings, central cardiovascular effects of ghrelin could be explained by the mechanisms of the activation of hypothalamic neuropeptide Y, and the antagonism of the MC3-R and MC4-R by activated AGRP.

Plasma ghrelin concentration has been shown to be decreased in obese patients⁴⁰ and to be increased in patients with cachexia associated with congestive heart failure,¹⁰ suggesting that plasma ghrelin concentration could be influenced by catabolic-anabolic balance. It has been reported that circulating levels of ghrelin are in the low nanogram range,^10,40 and data for ghrelin levels in CSF have not been available yet. In the present study, ghrelin levels in plasma and CSF were not determined. Therefore, it seems difficult to conclude that physiological levels of central ghrelin directly decrease arterial pressure and sympathetic activity. Neuropeptides participating in feeding behavior—such as leptin, neuropeptide Y, orexins, AGRP, and ghrelin—may function together to regulate sympathetic outflow and arterial pressure.

In conclusion, intravenous injection of a high dose of ghrelin (5 nmol) decreased arterial pressure and HR. ICV injection of a smaller dose of ghrelin (1 nmol) decreased arterial pressure and suppressed RSNA. Furthermore, ICV infusion of ghrelin augmented the baroreceptor control of RSNA and HR in conscious rabbits. These findings indicate that systemically administered ghrelin reaches the brain and modulates the sympathetic activity. The present study is an acute experiment; therefore, chronic studies are required to better elucidate the importance of ghrelin on the cardiovascular system. Further studies will be needed to determine the full physiological implications of the role of ghrelin on the regulations of appetite and sympathetic activity in the brain, especially in interaction with leptin.

Perspectives
Ghrelin is primarily found as an endogenous ligand for the GH secretagogue receptor and stimulates food intake.¹ Recent studies also demonstrated that systemically administered ghrelin decreases arterial pressure and increases cardiac index and stroke volume,⁹ suggesting that it participates in cardiovascular and sympathetic regulations. The present study demonstrates that central ghrelin suppressed sympathetic activity and augmented the baroreceptor reflex, although dose of ICV-injected ghrelin might not be in physiological range. However, the results of the present study support the idea that ghrelin may be beneficial effects for the treatment of the patients with hypertension or congestive heart failure. The effects of chronic administration of small dose of ghrelin on cardiovascular and sympathetic regulation should be determined in the near future.

Received May 29, 2002; first decision June 18, 2002; accepted August 19, 2002.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone–releasing acylated peptide from stomach. Nature. 1999; 402: 656–660.[CrossRef][Medline] [Order article via Infotrieve]

2. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001; 12: 118–122.[CrossRef][Medline] [Order article via Infotrieve]

3. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschöp M, Minireview. Ghrelin and the regulation of energy balance: a hypothalamic perspective. Endocrinology. 2001; 142: 4163–4169.[Abstract/Free Full Text]

4. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, Smith RG, Van der Ploeg LH, Howard AD. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Mol Brain Res. 1997; 48: 23–29.[Medline] [Order article via Infotrieve]

5. Bailey AR, Von Englehardt N, Leng G, Smith RG, Dickson SL. Growth hormone secretagogue activation of the arcuate nucleus and brainstem occurs via a non-noradrenergic pathway. J Neuroendocrinol. 2000; 12: 191–197.[CrossRef][Medline] [Order article via Infotrieve]

6. Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407: 908–913.[CrossRef][Medline] [Order article via Infotrieve]

7. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature. 2001; 409: 194–198.[CrossRef][Medline] [Order article via Infotrieve]

8. Ishizaki S, Murase T, Sugimura Y, Kakiya S, Yokoi H, Tachikawa K, Arima H, Miura Y, Oiso Y. Role of ghrelin in the regulation of vasopressin release in conscious rats. Endocrinology. 2002; 143: 1589–1593.[Abstract/Free Full Text]

9. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol. 2001; 280: R1483–R1487.

10. Nagaya N, Uematsu M, Kojima M, Date Y, Nakazato M, Okumura H, Hosoda H, Shimizu W, Yamagishi M, Oya H, Koh H, Yutani C, Kangawa K. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001; 104: 2034–2038.[Abstract/Free Full Text]

11. Okumura H, Nagaya N, Enomoto M, Nakagawa E, Oya H, Kangawa K. Vasodilatory effect of ghrelin, an endogenous peptide from the stomach. J Cardiovasc Pharmacol. 2002; 39: 779–783.[CrossRef][Medline] [Order article via Infotrieve]

12. Ishikawa N, Kallman CH, Sagawa K. Rabbit carotid sinus reflex under pentobarbital, urethan, and chloralose anesthesia. Am J Physiol. 1984; 246: H696–H701.[Medline] [Order article via Infotrieve]

13. Matsukawa K, Ninomiya I. Anesthetic effects on tonic and reflex renal sympathetic nerve activity in awake cats. Am J Physiol. 1989; 256: R371–R378.[Medline] [Order article via Infotrieve]

14. Matsumura K, Abe I, Tsuchihashi T, Tominaga M, Kobayashi K, Fujishima M. Central effect of endothelin on neurohormonal responses in conscious rabbits. Hypertension. 1991; 17: 1192–1196.[Abstract/Free Full Text]

15. Matsumura K, Abe I, Tsuchihashi T, Fujishima M. Central nitric oxide attenuates the baroreceptor reflex in conscious rabbits. Am J Physiol. 1998; 274: R1142–R1149.[Medline] [Order article via Infotrieve]

16. Matsumura K, Tsuchihashi T, Abe I. Central orexin-A augments sympathoadrenal outflow in conscious rabbits. Hypertension. 2001; 37: 1382–1387.[Abstract/Free Full Text]

17. Matsumura K, Tsuchihashi T, Abe I. Central human cocaine- and amphetamine-regulated transcript peptide 55–102 increases arterial pressure in conscious rabbits. Hypertension. 2001; 38: 1096–1100.[Abstract/Free Full Text]

18. Kent BB, Drane JW, Blumenstein B, Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology. 1972; 57: 295–310.[Medline] [Order article via Infotrieve]

19. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, Kojima M, Nakanishi N, Mori H, Kangawa K. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab. 2001; 86: 5854–5859.[Abstract/Free Full Text]

20. Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, Nakazato M. Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun. 2000; 275: 477–480.[CrossRef][Medline] [Order article via Infotrieve]

21. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DGA, Ghatei MA, Bloom SR. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology. 2000; 141: 4325–4328.[Abstract/Free Full Text]

22. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatini D, Marciano-Mone C, Sacca L, Bellastella A. Body composition, bone metabolism, and heart structure and function in growth hormone (GH)–deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab. 1993; 77: 1671–1676.[Abstract]

23. Volterrani M, Desenzani P, Lorusso R, d’Aloia A, Manelli F, Giustina A. Haemodynamic effects of intravenous growth hormone in congestive heart failure. Lancet. 1997; 349: 1067–1068.[CrossRef][Medline] [Order article via Infotrieve]

24. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y₁ receptor pathway. Diabetes. 2001; 50: 227–232.[Abstract/Free Full Text]

25. Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, Del Rio G, Arvat E, Boghen MF, Deghenghi R, Muccioli G, Ong H, Ghigo E. Acute cardiovascular and hormonal effects of GH and hexarelin, a synthetic GH-releasing peptide, in humans. J Endocrinol Invest. 1999; 22: 266–272.[Medline] [Order article via Infotrieve]

26. Date Y, Nakazato M, Murakami N, Kojima M, Kangawa K, Matsukura S. Ghrelin acts in the central nervous system to stimulate gastric acid secretion. Biochem Biophys Res Commun. 2001; 280: 904–907.[CrossRef][Medline] [Order article via Infotrieve]

27. Matsumura K, Tsuchihashi T, Kagiyama S, Abe I, Fujishima M. Subtypes of metabotropic glutamate receptors in the nucleus of the solitary tract of rats. Brain Res. 1999; 842: 461–468.[CrossRef][Medline] [Order article via Infotrieve]

28. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: hypothalamic control of food intake and body weight. Neuron. 1999; 22: 221–232.[CrossRef][Medline] [Order article via Infotrieve]

29. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1999; 69: 584–596.[Abstract/Free Full Text]

30. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Staels B, Auwerx J. Transient increase in obese gene expression after food intake or insulin administration. Nature. 1995; 377: 527–529.[CrossRef][Medline] [Order article via Infotrieve]

31. Sahu A. Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signaling in the hypothalamus. Endocrinology. 1998; 139: 795–798.[Abstract/Free Full Text]

32. Haynes WG, Sivitz WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions of leptin. Hypertension. 1997; 30: 619–623.[Abstract/Free Full Text]

33. Matsumura K, Abe I, Tsuchihashi T, Fujishima M. Central effects of leptin on cardiovascular and neurohormonal responses in conscious rabbits. Am J Physiol. 2000; 278: R1314–R1320.

34. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997; 46: 2040–2043.[Abstract]

35. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes. 2001; 50: 2438–2443.[Abstract/Free Full Text]

36. Matsumura K, Tsuchihashi T, Abe I. Central cardiovascular action of neuropeptide Y in conscious rabbits. Hypertension. 2000; 36: 1040–1044.[Abstract/Free Full Text]

37. Haskell-Luevano C, Monck EK. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Pept. 2001; 99: 1–7.[CrossRef][Medline] [Order article via Infotrieve]

38. Haynes WG, Morgan DA, Djalali A, Sivitz WI, Mark AL. Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension. 1999; 33: 542–547.[Abstract/Free Full Text]

39. Dunbar JC, Lu H. Leptin-induced increase in sympathetic nervous and cardiovascular tone is mediated by proopiomelanocortin (POMC) products. Brain Res Bull. 1999; 50: 215–221.[CrossRef][Medline] [Order article via Infotrieve]

40. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707–709.[Abstract/Free Full Text]

This article has been cited by other articles:

				M. Fry and A. V. Ferguson Ghrelin modulates electrical activity of area postrema neurons Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2009; 296(3): R485 - R492. [Abstract] [Full Text] [PDF]

				D. O. Schwenke, T. Tokudome, I. Kishimoto, T. Horio, M. Shirai, P. A. Cragg, and K. Kangawa Early Ghrelin Treatment after Myocardial Infarction Prevents an Increase in Cardiac Sympathetic Tone and Reduces Mortality Endocrinology, October 1, 2008; 149(10): 5172 - 5176. [Abstract] [Full Text] [PDF]

				M. Yukawa, D. S. Weigle, C. D. Davis, B. T. Marck, and T. Wolden-Hanson Peripheral ghrelin treatment stabilizes body weights of senescent male Brown Norway rats at baseline and after surgery Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2008; 294(5): R1453 - R1460. [Abstract] [Full Text] [PDF]

				T. Soeki, I. Kishimoto, D. O. Schwenke, T. Tokudome, T. Horio, M. Yoshida, H. Hosoda, and K. Kangawa Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2008; 294(1): H426 - H432. [Abstract] [Full Text] [PDF]

				R. Wu, M. Zhou, P. Das, W. Dong, Y. Ji, D. Yang, M. Miksa, F. Zhang, T. S. Ravikumar, and P. Wang Ghrelin inhibits sympathetic nervous activity in sepsis Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1697 - E1702. [Abstract] [Full Text] [PDF]

				H. Hashimoto, H. Fujihara, M. Kawasaki, T. Saito, M. Shibata, H. Otsubo, Y. Takei, and Y. Ueta Centrally and Peripherally Administered Ghrelin Potently Inhibits Water Intake in Rats Endocrinology, April 1, 2007; 148(4): 1638 - 1647. [Abstract] [Full Text] [PDF]

				E. Grossini, C. Molinari, D. A. S. G. Mary, E. Ghigo, G. Bona, and G. Vacca Intracoronary Ghrelin Infusion Decreases Coronary Blood Flow in Anesthetized Pigs Endocrinology, February 1, 2007; 148(2): 806 - 812. [Abstract] [Full Text] [PDF]

				M. Tanida, A. Niijima, J. Shen, S. Yamada, H. Sawai, Y. Fukuda, and K. Nagai Dose-different effects of orexin-a on the renal sympathetic nerve and blood pressure in urethane-anesthetized rats. Experimental Biology and Medicine, November 1, 2006; 231(10): 1616 - 1625. [Abstract] [Full Text] [PDF]

				M. J. Carlson and D. E. Cummings Prospects for an anti-ghrelin vaccine to treat obesity. Mol. Interv., October 1, 2006; 6(5): 249 - 252. [Abstract] [Full Text] [PDF]

				S. S. Damjanovic, N. M. Lalic, P. M. Pesko, M. S. Petakov, A. Jotic, D. Miljic, K. S. Lalic, L. Lukic, M. Djurovic, and V. B. Djukic Acute Effects of Ghrelin on Insulin Secretion and Glucose Disposal Rate in Gastrectomized Patients J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2574 - 2581. [Abstract] [Full Text] [PDF]

				N. Nagaya, T. Itoh, S. Murakami, H. Oya, M. Uematsu, K. Miyatake, and K. Kangawa Treatment of Cachexia With Ghrelin in Patients With COPD Chest, September 1, 2005; 128(3): 1187 - 1193. [Abstract] [Full Text] [PDF]

				M. Kojima and K. Kangawa Ghrelin: Structure and Function Physiol Rev, April 1, 2005; 85(2): 495 - 522. [Abstract] [Full Text] [PDF]

				N. Nagaya, J. Moriya, Y. Yasumura, M. Uematsu, F. Ono, W. Shimizu, K. Ueno, M. Kitakaze, K. Miyatake, and K. Kangawa Effects of Ghrelin Administration on Left Ventricular Function, Exercise Capacity, and Muscle Wasting in Patients With Chronic Heart Failure Circulation, December 14, 2004; 110(24): 3674 - 3679. [Abstract] [Full Text] [PDF]

				L. M. Hunt, E. W. Hogeland, M. K. Henry, and S. J. Swoap Hypotension and bradycardia during caloric restriction in mice are independent of salt balance and do not require ANP receptor Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1446 - H1451. [Abstract] [Full Text] [PDF]

				K. A. Brownley, K. C. Light, K. M. Grewen, E. E. Bragdon, A. L. Hinderliter, and S. G. West Postprandial Ghrelin Is Elevated in Black Compared with White Women J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4457 - 4463. [Abstract] [Full Text] [PDF]

				M. J Iglesias, R. Pineiro, M. Blanco, R. Gallego, C. Dieguez, O. Gualillo, J. R Gonzalez-Juanatey, and F. Lago Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes Cardiovasc Res, June 1, 2004; 62(3): 481 - 488. [Abstract] [Full Text] [PDF]

				Y. Lin, K. Matsumura, M. Fukuhara, S. Kagiyama, K. Fujii, and M. Iida Ghrelin Acts at the Nucleus of the Solitary Tract to Decrease Arterial Pressure in Rats Hypertension, May 1, 2004; 43(5): 977 - 982. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 40/5/694    most recent 01.HYP.0000035395.51441.10v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Matsumura, K. Articles by Iida, M. Search for Related Content PubMed PubMed Citation Articles by Matsumura, K. Articles by Iida, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Autonomic, reflex, and neurohumoral control of circulation